Translation of "Goserelin" in German

This includes gonadorelin, buserelin, goserelin, leuprorelin and triptorelin.

The prostate volume reduction was similar to that attained with goserelin plus anti-androgen protection.

The active ingredient of the agent is goserelin.

Examples of preferred hormones and antagonists thereof are flutamide, goserelin, mitotane or tamoxifen.

The Bachem Group announced the renewal of its supply agreement with AstraZeneca for the peptide active substance Goserelin.

Overall summary of the scientific evaluation of Novosis Goserelin 3,6 mg Implantat and associated names (see Annex I)

In view of the number and the seriousness of the deficiencies, the extent of deviations of the measured serum concentrations of both, goserelin and testosterone from the actual concentrations, cannot be estimated.

During the evaluation of the marketing authorisation application of some goserelin-containing medicinal products inconsistencies were recognised (e.g. assignment of patients to blood samples unclear).

In view of all these facts the MAH requested the CHMP to confirm the acceptability of the existing clinical package for goserelin and maintain the marketing authorization for the concerned products.

The results of these studies were submitted in a number of marketing authorisation applications of goserelin-containing generic medicinal products to demonstrate therapeutic equivalence with the reference product Zoladex in the course of a MAA under Article.

Goserelin is among others, authorised for patients with advanced prostate cancer where an endocrine treatment is indicated.

In spite of the fact that patient safety and product efficacy was always ensured, the MAH decided to clinically reinvestigate the current goserelin 1-month product.

The following substances are available for treating hormone-dependent malignant diseases; ZoladexRTM (INN: Goserelin) and DecapeptylRTM (INN: Triptorelin).

Examples of hormones are gonadotropin (follitropin, lutropin, chorionic gonadotropin, menotropin), somatropin, desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin, goserelin.

Examples of LHRH-/GnRH-antagonists which may be used in the combination of active substances according to the invention are preferably the active substances goserelin, desorelin, cetrorelix or gonadorelin.

The LHRH/GnRH antagonist may be selected from the group consisting of the active substances goserelin, desorelin, cetrorelix and gonadorelin.

Then, in a second step, a TTS with a GnRH agonist (for example, leuprolide, buserelin, nafarelin, histrelin, goserelin or deslorelin, but preferably triptorelins) is applied to the skin location thus treated and is left on this skin location for a relatively long time period (at least 12 hours, preferably 24 to 48 hours).

Examples for hormones are glucocorticoids (prednisone), estrogens (fosfestrol, estramustine), LHRH (buserelin, goserelin, leuprorelin, triptorelin), flutamide, cyproterone acetate, tamoxifen, toremifen, aminoglutethimide, formestane, exemestane, letrozole and anastrozole.

According to the invention, hormones such as for example glucocorticoids (prednisone), estrogens (fosfestrol, estramustine), LHRH (buserelin, goserelin, leuprorelin, triptorelin), flutamide, cyproterone acetate, tamoxifen, toremifen, aminoglutethimide, formestane, exemestane, letrozole and anastrozole can also be used.

The oral multiparticulate pharmaceutical form of claim 7, wherein the active substance is selected from the group consisting of abarelix angiogenesis II, anidulafungin, antide, argipressin, azaline and azaline B, bombesin antagonist, bradykinin, buserelin, cetrorelix, cyclosporin A, desmopressin, detirelix, encephalins (Leu-, Met-) ganirelix, gonadorelin, goserelin, growth hormone secretagogue, micafungin, nafarelin, leuprolide, leuprorelin, octreotide, orntide, oxytocin, ramorelix, secretin, somatotropin, terlipressin, tetracosactide, teverelix, triptorelin, thyroliberin, thyrotropin, vasopressin and mixtures thereof.

The pharmaceutical preparation according to claim 1, wherein a chemotherapeutic agent which is docetaxel, paclitaxel, carboplatin, cisplatin, 5-FU and calcium folinate, irinotecan, cyclophosphamide, carmustine, doxorubicin, vinorelbine, goserelin or gemcitabine is employed.

Particular preference is given to a pharmaceutical preparation as described, characterized in that a chemotherapeutic agent from a group consisting of docetaxel, paclitaxel, carboplatin, cisplatin, 5-FU and calcium folinate, irinotecan, cyclophosphamide, carmustine, doxorubicin, vinorelbine, goserelin or gemcitabine is employed.

A therapy with a Gonadotropinreleasing hormone agonist (Goserelin, Zoladex®) was started instead and resulted in a significant regression of the tumor.

The PROFE study was conducted to compare oral contraceptives and the GnRH analogue, goserelin, regarding their ability to reduce ovarian toxicity and thus treatment-induced infertility.

The active substance may be a protein or a peptide having an average molecular weight M w of less than 3000 Da. Examples of such peptides are in particular abarelix, angiotensin II, anidulafungin, antide, argipressin, azaline and azaline B, bombesin antagonist, bradykinin, buserelin, cetrorelix, cyclosporine A, desmopressin, detirelix, encephalins (Leu-, Met-) ganirelix, gonadorelin, goserelin, growth hormone secretagogue, micafungin, nafarelin, leuprolide, leuprorelin, octreotide, orntide, oxytocin, ramorelix, secretin, somatotropin, terlipressin, tetracosactide, teverelix, triptorelin, thyroliberin, thyrotropin, vasopressin.

Similar results to those described by Emons et al., Cancer Research, 53, 1993, 539-544, and Irmer, G., et al., supra, were obtained. Separately, the above-mentioned cell lines were also treated with an GnRH agonist, either with GOSERELIN® (ZOLADEX®, Buserelin or LEUPRORELIN®) or with a GnRH antagonist such as Antide® or Antarelix®.